TLR7 and systemic lupus erythematosus: TLR-7 activation via epicutaneous treatment with the TLR-7 agonists imiquimod or resiquimod induces SLE-like systemic autoimmune disease in mice of different genetic backgrounds (Yokogawa et al., 2014).